Umlaut.bio
Key Facts
| Invested since | 2024 |
| Based in | Baden-Württemberg |
About the company
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – chemically modified RNA nucleotides. These play a crucial role in gene regulation and are of great importance, for example, in cancer cells. There, modified tRNAs protect protein-coding mRNAs from degradation and thus promote tumor growth. Therapeutic modalities that specifically address this mechanism could be able to selectively prevent the growth of cancer cells. This approach promises a disruptive novel form of cancer therapy that could offer a new, gentler treatment option for many patients.
Do you want to
know more about this company?
Umlaut.bio in the news
More startups from Life Sciences
CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.
To the complete profileof CorTec
C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential …
To the complete profileof C-mo
Exit
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
To the complete profileof Fiagon
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. …
To the complete profileof NUMAFERM
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …
To the complete profileof SRTD biotech
IPO
Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. …
To the complete profileof Immunic
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …
To the complete profileof Biograil
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
To the complete profileof HAPILA
inContAlert was founded in September 2022 within the ecosystem of the University of Bayreuth. The MedTech startup’s sensor system empowers patients with neurogenic bladder dysfunction to manage their bladder on …
To the complete profileof inContAlert
Exit
GME German Medical Engineering develops and markets a new generation of laser and lightsystems (small, light weight, modular) for the use in cosmetic and medical dermatology.
To the complete profileof GME